

FORM PTO-1449/A and B (Modified)

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

APPLICATION NO.: 09/818,918

ATTY. DOCKET NO.: C1039.70048US00

FILING DATE: March 27, 2001

CONFIRMATION NO.: 4953

APPLICANT: Krieg et al.

GROUP ART UNIT: ~~1645~~ 1645

EXAMINER: ~~James H. Minnifield~~ Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>MM</i>	A45	5,955,059		Gilchrest et al.	09-21-1999

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)


EXAMINER: *MM Minnifield*

DATE CONSIDERED: *11-9-04*

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/818,918	ATTY. DOCKET NO.: C1039.70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 27, 2001	CONFIRMATION NO.: 4953
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 164 1645	EXAMINER: James Minnifield
Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
mm	C1	Patent Interference No. 105,171. Miscellaneous Motion 1 (Unopposed Additional Request for Copies of the Histories). April 15, 2004.		
mm	C2	Patent Interference No. 105,171. Miscellaneous Motion 2 (Unopposed Request for Addition to Iowa's File History). April 15, 2004.		
mm	C3	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for Judgment Based on Failure to Comply with 35 U.S.C. 135(b)) (Electronically filed, unsigned). June 7, 2004.		
mm	C4	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (For Judgment of No Interference in Fact) (Electronically filed, unsigned). June 7, 2004.		
mm	C5	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (For Judgment Based on Lack of Enablement) (Electronically filed, unsigned). June 7, 2004.		
mm	C6	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (For Judgment Based Lack of an Adequate Written Description) (Electronically filed, unsigned). June 7, 2004.		
mm	C7	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (Motion to Redefine the Interference to Designate Claims as Not Corresponding to the Count) (Electronically filed, unsigned). June 7, 2004.		
mm	C8	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (Contingent Motion to Redefine Count) (Electronically filed, unsigned). June 7, 2004.		
mm	C9	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (Motion for Benefit of Earlier Application) (Electronically filed, unsigned). June 7, 2004.		
mm	C10	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (Contingent Motion to Redefine the Interference By Adding A Continuation Application) (Electronically filed, unsigned). July 2, 2004.		
mm	C11	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.		
mm	C12	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (To Designate Additional Claims of the Iowa Patent as Corresponding to the Count). June 7, 2004.		
mm	C13	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (For Judgment Based on Lack of Written Description Support and Introducing New Matter). June 7, 2004.		
mm	C14	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (For Judgment Based on Obviousness). June 7, 2004.		

DO NOT PRINT

N.M. Minnifield 11-9-04

DO NOT PRINT



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/818,918	ATTY. DOCKET NO.: C1039.70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 27, 2001	CONFIRMATION NO.: 4953
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645 1645	EXAMINER: 1645 Minnifield
Sheet	2	of	2

MM	C14	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (For Judgment Based on Anticipation). June 7, 2004.		
MM	C16	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (For Judgment Based on Inequitable Conduct). June 7, 2004.		
MM	C17	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 7 (For Benefit of an Earlier Application under 37 CFR 1.633(j)). July 2, 2004.		
MM	C18	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 8 (For Add Additional Claims Under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.		
MM	C19	Amended Claims for Application Number 09/818,918, filed March 10, 1999		

EXAMINER <i>N.M. Minnifield</i>	DATE CONSIDERED <i>11-9-04</i>
---------------------------------	--------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified) **AUG 23 2004**

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/818,918

FILING DATE: March 27, 2001

ATTY. DOCKET NO.: C1039.70048US00

CONFIRMATION NO.: 4953

APPLICANT: Krieg et al.

GROUP ART UNIT: ~~1045~~ 1645

EXAMINER: ~~John~~ Minni Field

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
mm	A27	6,086,898	B1	DeKruyff et al.	07-11-2000
mm	A28	2002/0064515	A1	Krieg et al.	05-30-2002
mm	A29	2003/0026782	A1	Krieg et al.	02-06-2003
mm	A30	2003/0050261	A1	Krieg et al.	03-13-2003
mm	A31	2003/0050268	A1	Krieg et al.	03-13-2003
mm	A32	2003/0087848	A1	Bratzler et al.	05-08-2003
mm	A33	6,653,292	B1	Krieg et al.	11-05-2003
mm	A34	2003/0232074	A1	Lipford et al.	12-18-2003
mm	A35	2004/0009949	A1	Krieg	01-15-2004
mm	A36	2004/0030118	A1	Wagner et al.	02-12-2004
mm	A37	2004/0053880	A1	Krieg	03-18-2004
mm	A38	2004/0067905	A1	Krieg	04-08-2004
mm	A39	6,727,230	B1	Hutcherson et al.	04-27-2004
mm	A40	2004/0087534	A1	Krieg et al.	05-06-2004
mm	A41	2004/0087538	A1	Krieg et al.	05-06-2004
mm	A42	2004/0092472	A1	Krieg	05-13-2004
mm	A43	2004/0131628	A1	Bratzler et al.	07-08-2004
mm	A44	2004/0132685	A1	Krieg et al.	07-08-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
mm	B9	WO	98/18810	A1		05-07-1998	
mm	B10	WO	98/37919	A1		09-03-1998	
mm	B11	WO	98/40100	A1		09-17-1998	
mm	B12	WO	98/52581	A1		11-26-1998	
mm	B13	WO	99/51259	A2		10-14-1999	
mm	B14	WO	99/61056	A2		12-02-1999	
mm	B15	WO	00/54803	A2		09-21-2000	
mm	B16	WO	01/22972	A2		04-05-2001	
mm	B17	WO	01/95935	A1		12-20-2001	
mm	B18	WO	01/97843	A2		12-27-2001	
mm	B19	WO	02/22809	A2		03-21-2002	
mm	B20	WO	02/053141	A2		07-11-2002	
mm	B21	WO	03/012061	A2		02-13-2003	
mm	B22	WO	03/015711	A2		02-27-2003	
mm	B23	WO	03/031573	A2		04-17-2003	
mm	B24	WO	03/103586	A2		12-18-2003	
mm	B25	WO	2004/007743	A2		01-22-2004	

MM Minni Field

11-9-04

O I P E

FORM PTO-1449/A and B (Modified) **AUG 23 2004**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/818,918

ATTY. DOCKET NO.: C1039.70048US00

FILING DATE: March 27, 2001

CONFIRMATION NO.: 4953

APPLICANT: Krieg et al.

GROUP ART UNIT: ~~1005~~ 1645

EXAMINER: ~~James~~ Minnifield

Sheet 2 of 3

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
MM	C20	ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.	
MM	C21	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
MM	C22	Allergen Nomenclature, List of allergens (as of March 12, 2004).	
MM	C23	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
MM	C24	DUNN et al., The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60. Review.	
MM	C25	DURHAM et al., Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.	
MM	C26	FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol. 1988 Sep;48(3):297-306.	
MM	C27	FRISSORA et al., IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. Eur J Immunol. 2003 Apr;33(4):907-12.	
MM	C28	JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol. 2001 Mar 1;166(5):3612-21.	
MM	C29	KUBY et al., Editors, "Chapter 13: Cytokines", Immunology: Second Edition, W.H. Freeman and Company, New York. 1994. p297-322.	
MM	C30	LIEBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.	
MM	C31	LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. J Rheumatol. 1987 Feb;14(1):42-5.	
MM	C32	MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002 Sep 10;20(27-28):3263-71.	
MM	C33	MARDH et al., Alternaria alternata as a cause of opportunistic fungal infections in man. Scand J Infect Dis Suppl. 1978;(16):36-40.	
MM	C34	METZGER et al., Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:100-15.	
MM	C35	MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol. 1985 Oct;135(4):2513-7.	
MM	C36	PISETSKY et al., Mechanisms of autoantibody production in autoimmune MRL mice. J Exp Med. 1980 Nov 1;152(5):1302-10.	
MM	C37	RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5141-5.	
MM	C38	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. J Immunol. 1987 Aug 1;139(3):767-73.	
MM	C39	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4.	
MM	C40	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12. Review.	
MM	C41	WALLNER et al., Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy. 1994 May;49(5):302-8.	

MM Minnifield

11-9-04

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/818,918	ATTY. DOCKET NO.: C1039,70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 27, 2001	CONFIRMATION NO.: 4953
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 164 1645	EXAMINER: J. Minnifield Minnifield
Sheet	3	of	3

<i>MM</i>	C42	WEERATNA et al., Optimization strategies for DNA vaccines. Intervirology. 2000;43(4-6):218-26.		
<i>MM</i>	C43	WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci. 1995 Nov 27;772:64-76.		
<i>MM</i>	C44	ZHANG et al., Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. J Immunol. 1993 Jul 15;151(2):791-9.		


EXAMINER: <i>MM Minnifield</i>	DATE CONSIDERED: 11-9-04
--------------------------------	--------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/818,918	ATTY. DOCKET NO.: C1039.70048US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 27, 2001	CONFIRMATION NO.: 4953
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645 1645	EXAMINER: James E. Minnifield Minnifield
Sheet	1	of	1



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>MM</i>	A7	2001/0044416	A1	Davis et al.	11-22-2001
<i>MM</i>	A8	2003/0055014	A1	Bratzler	03-20-2002
<i>MM</i>	A9	6,406,705	B1	Davis et al.	06-18-2002
<i>MM</i>	A10	2002/0091097	A1	Bratzler et al.	07-11-2002
<i>MM</i>	A11	6,429,199	B1	Krieg et al.	08-06-2002
<i>MM</i>	A12	2002/0156033	A1	Bratzler et al.	10-24-2002
<i>MM</i>	A13	2002/0164341	A1	Davis et al.	11-07-2002
<i>MM</i>	A14	2002/0165178	A1	Schetter et al.	11-07-2002
<i>MM</i>	A15	2002/0198165	A1	Bratzler et al.	12-26-2002
<i>MM</i>	A16	2003/0026801	A1	Weiner et al.	02-06-2003
<i>MM</i>	A17	2003/0050263	A1	Krieg et al.	03-13-2003
<i>MM</i>	A18	2003/0091599	A1	Davis et al.	05-15-2003
<i>MM</i>	A19	2003/0100527	A1	Krieg et al.	05-29-2003
<i>MM</i>	A20	2003/0104523	A1	Lipford et al.	06-05-2003
<i>MM</i>	A21	2003/0139364	A1	Krieg et al.	07-24-2003
<i>MM</i>	A22	2003/0148976	A1	Krieg et al.	08-07-2003
<i>MM</i>	A23	2003/0148316	A1	Lipford et al.	08-07-2003
<i>MM</i>	A24	2003/0166001	A1	Lipford	09-04-2003
<i>MM</i>	A25	2003/0181406	A1	Schetter et al.	09-25-2003
<i>MM</i>	A26	2003/0191079	A1	Krieg et al.	10-09-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>MM</i>	B1	WO	98/32462	A1		07-30-1998	
<i>MM</i>	B2	WO	99/56755	A1		11-11-1999	
<i>MM</i>	B3	WO	99/58118	A2		11-18-1999	
<i>MM</i>	B4	WO	00/06588	A1		02-10-2000	
<i>MM</i>	B5	WO	00/14217	A3		03-16-2000	
<i>MM</i>	B6	WO	00/67023	A1		11-09-2000	
<i>MM</i>	B7	WO	01/22990	A2		04-05-2001	
<i>MM</i>	B8	WO	02/069369	A2		09-06-2002	

EXAMINER: <i>MM Minnifield</i>	DATE CONSIDERED: <i>11-9-04</i>
--------------------------------	---------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).